Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 49
- Registration Number
- NCT00987493
- Locations
- 🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭Stadtspital Triemli, Zürich, Switzerland
🇨🇭Kantonsspital Baden, Baden, Switzerland
Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 23
- Registration Number
- NCT00977132
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Klinik für Innere Medizin III, Ulm, Bayern, Germany
🇩🇪Medizinische Universitätsklinik Freiburg, Abteilung Innere Medizini, Freiburg, Baden Würtemberg, Germany
🇩🇪Georg-August-Universität,Universitätsklinikum - Abteilung Hämatologie und Onkologie, Goettingen, Niedersachsen, Germany
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT00975806
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Cleveland Clinic Main Campus, Cleveland, Ohio, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
- Conditions
- Interventions
- First Posted Date
- 2009-09-10
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 34
- Registration Number
- NCT00974233
- Locations
- 🇺🇸
Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin, United States
🇺🇸Gundersen Clinic, La Crosse, Wisconsin, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT00966693
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-08-21
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Celgene
- Target Recruit Count
- 104
- Registration Number
- NCT00963105
- Locations
- 🇺🇸
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States
🇺🇸Cancer Center of Central Connecticut, Southington, Connecticut, United States
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 63
- Registration Number
- NCT00942578
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Robert Dreicer MD
- Target Recruit Count
- 32
- Registration Number
- NCT00939510
- Locations
- 🇺🇸
Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Lenalidomide and Paclitaxel in Prostate Cancer
- First Posted Date
- 2009-07-07
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00933426
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 25
- Registration Number
- NCT00928486
- Locations
- 🇯🇵
Nagoya Medical Center, Nagoya-city, Aichi, Japan
🇯🇵Niigata Cancer Center Hospital, Niigata-city, Niigata, Japan
🇯🇵Keio University Hospital, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.